Abstract:Objective: To explore the effect of Feng-liao-chang-wei-kang (FLCWK) on acute and chronic gastroenteritis, synergistic effect on the growth inhibitory effect with 5-fluorouracil (5-FU) on colorectal cancer and its underlying mechanisms. Methods: In the in vitro study, HT-29 cells were divided into 5-FU alone, FLCWK alone and coadministration groups. The MTT assay was used to analyze the proliferation of HT-29 cells at 24 h. Flow cytometry was used to observe the apoptosis, cycle of colorectal cancer HT29 cells at 24 h. In the in vivo experiment, The subcutaneous transplantation tumor model of colorectal cancer HT-29-Luc was established with nude mice. All mice were randomly divided into 5-FU alone, FLCWK alone and coadministration groups according to body weight. During administration, the Interactive Video Information System small animal live imaging system was used to monitor the growth of subcutaneous transplantation in nude mice. The model of colitis-associated colorectal cancer (CACC) was established with BALB/c mice. BALB/c mice were randomly divided into the normal control group, the model control group, and the FLCWK group. At the end of the administration, the pathological status was detected by HE staining. Cell apoptosis of tumor tissue tumor and colon tissues were observed by TUNEL staining and TUNEL green fluorescence. The protein expression of Caspase 3, p-STAT3, Bcl-2, Bax and P-gp in tumor tissues tumor and colon tissues were tested by using immunohistochemical assay. Results: FLCWK and 5-FU coadministration suppressed HT-29 cell viability and induced S phase arrest and apoptosis compared to treatment with 5-FU alone. Furthermore, compared to treatment with 5-FU alone, coadministration of FLCWK and 5-FU obviously reduced tumor volume and weight and induced apoptosis through decreasing p-STAT3 and P-gp and increasing Caspase 3 protein expression in a murine xenograft tumor model. Moreover, the result revealed decreased number and size of tumors following FLCWK protective administration, downregulated p-STAT3 and Bcl-2 levels and upregulated Bax and Caspase 3 expression in mice with CACC. Conclusions: FLCWK has synergistic effects with 5-FU on colorectal cancer by suppressing the STAT3 pathway and downregulating P-gp expression. Furthermore, FLCWK administration suppresses CACC tumorigenesis by inhibiting the STAT3 pathway.

Synergistic Antitumor Effect of 5-Fluorouracil with the Novel LSD1 Inhibitor ZY0511 in Colorectal Cancer

ZY0511, a Novel, Potent and Selective LSD1 Inhibitor, Exhibits Anticancer Activity Against Solid Tumors Via the DDIT4/mTOR Pathway.

Lipidomic profiling reveals lipid regulation by a novel LSD1 inhibitor treatment

Combination of ZD55-MnSOD therapy with 5-FU enhances antitumor efficacy in colorectal cancer

BZD9L1 sirtuin inhibitor as a potential adjuvant for sensitization of colorectal cancer cells to 5-fluorouracil

Pharmacological Inhibition of LSD1 Suppresses Growth of Hepatocellular Carcinoma by Inducing GADD45B

The novel LSD1 inhibitor ZY0511 suppresses diffuse large B-cell lymphoma proliferation by inducing apoptosis and autophagy

Progress of synergistic factors of histone lysine specific demethylase 1 in colorectal cancer

Retraction Note: Inhibition of EZH2 Enhances the Therapeutic Effect of 5-FU Via PUMA Upregulation in Colorectal Cancer

Ursolic Acid Synergistically Enhances the Therapeutic Effects of Oxaliplatin in Colorectal Cancer

Tenacissoside G Synergistically Potentiates Inhibitory Effects of 5-Fluorouracil to Human Colorectal Cancer.

The combination of FLCWK with 5‐FU inhibits colon cancer and multidrug resistance by activating PXR to suppress the IL‐6/STAT3 pathway

Design, Synthesis, and Structure-Activity Relationship of Novel LSD1 Inhibitors Based on Pyrimidine-Thiourea Hybrids As Potent, Orally Active Antitumor Agents.

Feng-liao-chang-wei-kang is Synergistic with 5-Fluorouracil in Inhibiting Proliferation of Colorectal Cancer

Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer

P1.03-25 Synergistic Lethality of Ferroptosis Inducer-Disulfiram/Copper Complex and WEE1 Kinase Inhibitor for RAS/TP53 Mutant NSCLC

Inhibition of lysine-specific demethylase 1 enhances the sensitivity of the chemotherapeutic drug doxorubicin in gastric cancer cell

Synergistic Antitumor Activity of Regorafenib and Lapatinib in Preclinical Models of Human Colorectal Cancer.

Syntheses of LSD1/HDAC Inhibitors with Demonstrated Efficacy against Colorectal Cancer: In Vitro and In Vivo Studies Including Patient-Derived Organoids

Inhibition of NLRP3 inflammasome activation in myeloid-derived suppressor cells by andrographolide sulfonate contributes to 5-FU sensitization in mice

Targeting Colorectal Cancer with Conjugates of a Glucose Transporter Inhibitor and 5-Fluorouracil